UK Markets closed
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • FTSE 250

    22,472.04
    +116.59 (+0.52%)
     
  • AIM

    1,248.13
    +4.22 (+0.34%)
     
  • GBP/EUR

    1.1515
    +0.0004 (+0.04%)
     
  • GBP/USD

    1.3784
    -0.0001 (-0.0041%)
     
  • BTC-GBP

    44,912.52
    -1,329.64 (-2.88%)
     
  • CMC Crypto 200

    1,397.85
    +16.90 (+1.22%)
     
  • S&P 500

    4,170.42
    +45.76 (+1.11%)
     
  • DOW

    34,035.99
    +305.10 (+0.90%)
     
  • CRUDE OIL

    63.37
    -0.09 (-0.14%)
     
  • GOLD FUTURES

    1,764.90
    -1.90 (-0.11%)
     
  • NIKKEI 225

    29,642.69
    +21.70 (+0.07%)
     
  • HANG SENG

    28,793.14
    -107.69 (-0.37%)
     
  • DAX

    15,255.33
    +46.18 (+0.30%)
     
  • CAC 40

    6,234.14
    +25.56 (+0.41%)
     

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming virtual investor conferences:

  • The H.C. Wainwright Global Life Sciences Conference on March 9, 2021, on-demand beginning at 7:00 a.m. ET; and

  • The Oppenheimer Virtual 31st Annual Healthcare Conference on March 17, 2021 at 9:20 a.m. ET.

A live webcast of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005055/en/

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com